CStone Pharmaceuticals (HK:2616) has released an update.
CStone Pharmaceuticals has entered a strategic partnership with Pharmalink for the commercialization of sugemalimab in the Middle East, North Africa, and South Africa, expanding its global market reach. This collaboration will see CStone receiving milestone payments and royalties, while Pharmalink handles regulatory activities. Sugemalimab, a promising treatment for various cancers, continues to gain traction internationally, with further partnerships expected in other regions.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.